Scholars Central

Review articlePublished 6 Jul 2016

Personalized therapy for urothelial cancer: review of the clinical evidence

Authors: Elizabeth A Guancial, Dipanjan Chowdhury, Jonathan E Rosenberg

Clinical Investigation

Volume 1 · Issue 4 · Pages 543

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Despite a detailed understanding of the molecular aberrations driving the development of urothelial cancers, this knowledge has not translated into advances for the treatment of this disease. Urothelial cancers are chemosensitive and platinum-based combination chemotherapy remains the standard of care for advanced disease, as well as neoadjuvant and adjuvant therapy for locally advanced disease. However, nearly half of patients who undergo resection of locally advanced urothelial cancer will relapse and eventually develop platinum-resistant disease. Clinical trials of targeted agents against angiogenesis and growth factors, as well as novel chemotherapeutics, have generally been unsuccessful in urothelial cancers. Improvements in the therapeutic arsenal for urothelial cancer depend upon identification of new targets and strategies to overcome platinum resistance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Elizabeth A Guancial”
  • BylineArticles whose byline prints “Dipanjan Chowdhury”
  • BylineArticles whose byline prints “Jonathan E Rosenberg”